Suppr超能文献

应用群体机制模型寻找初治淋巴瘤患者嵌合抗原受体T细胞动力学的决定因素。

Applying population mechanistic modelling to find determinants of chimeric antigen receptor T-cells dynamics in month-one lymphoma patients.

作者信息

Brown Liam V, McConnell Mark, Rosler Robert, Peiser Leanne, Schmidt Brian J, Ratushny Alexander V, Gaffney Eamonn A, Coles Mark C

机构信息

Wolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, United Kingdom.

Kennedy Institute of Rheumatology, University of Oxford, United Kingdom.

出版信息

Immunother Adv. 2025 Jun 9;5(1):ltaf001. doi: 10.1093/immadv/ltaf001. eCollection 2025.

Abstract

BACKGROUND

Chimeric antigen receptor (CAR) T-cells have been utilized for the treatment of several malignancies, including Non-Hodgkin lymphomas. A myriad of product- and patient-specific factors determines the extent of patient response, and determining which are most impactful requires analysis of clinical data.

METHODS

We used population-level ordinary differential equation models to fit clinical flow cytometry and tumour biopsy data from the TRANSCEND-NHL-001 (NCT02631044) study [1]. We analyzed the impact of lymphodepletion, CAR T-cell phenotypes, and other factors on CAR T-cell dynamics for 30 days after infusion.

RESULTS

We quantified the relative contribution of antigen-dependent and independent sources of proliferation on CAR T-cell dynamics, finding that both make a large contribution and that antigen-independent proliferation was highly correlated with patient IL-15 and IL-7 blood concentrations. The proportion of CAR T-cells in naïve, memory, or effector cells was found to have a limited impact on CAR T-cell dynamics, compared with lymphodepletion and tumour burden.

CONCLUSIONS

This study shows how models can be used to link endogenous T-cells, CAR T-cells, and their phenotypes, and may be useful for determining whether a given patient may be responding poorly to treatment, by observing the dynamics of their endogenous T-cells. The framework we developed can be utilized for other CAR T constructs and indications, to test product alterations or biological hypotheses at the population level.

摘要

背景

嵌合抗原受体(CAR)T细胞已被用于治疗多种恶性肿瘤,包括非霍奇金淋巴瘤。众多产品和患者特异性因素决定了患者的反应程度,而确定哪些因素影响最大需要分析临床数据。

方法

我们使用群体水平的常微分方程模型来拟合来自TRANSCEND-NHL-001(NCT02631044)研究的临床流式细胞术和肿瘤活检数据[1]。我们分析了淋巴细胞清除、CAR T细胞表型及其他因素对输注后30天内CAR T细胞动力学的影响。

结果

我们量化了抗原依赖性和非依赖性增殖来源对CAR T细胞动力学的相对贡献,发现两者都有很大贡献,且非抗原依赖性增殖与患者血液中IL-15和IL-7浓度高度相关。与淋巴细胞清除和肿瘤负荷相比,发现初始、记忆或效应细胞中CAR T细胞的比例对CAR T细胞动力学的影响有限。

结论

本研究展示了如何使用模型来关联内源性T细胞、CAR T细胞及其表型,并且通过观察内源性T细胞的动力学,可能有助于确定特定患者对治疗的反应是否不佳。我们开发的框架可用于其他CAR T构建体和适应症,以在群体水平上测试产品改变或生物学假设。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9914/12362351/72dbdb830852/ltaf001_fig6.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验